



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 1 227 084 A1

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
31.07.2002 Bulletin 2002/31

(21) Application number: 00970155.8

(22) Date of filing: 27.10.2000

(51) Int Cl.⁷: C07D 213/30, C07D 277/26,
C07D 277/28, C07D 277/32,
C07D 277/44, C07D 215/14,
C07D 215/56, C07D 307/52,
C07D 513/04, C07D 263/56,
C07D 417/04

(86) International application number:
PCT/JP00/07565

(87) International publication number:
WO 01/30757 (03.05.2001 Gazette 2001/18)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 28.10.1999 US 428486
28.10.2000 JP 2000326713

(71) Applicants:
• Microcide Pharmaceuticals, Inc.
Mountainview, CA 94043 (US)
• DAIICHI PHARMACEUTICAL CO., LTD.
Chuo-ku, Tokyo 103-8234 (JP)

(72) Inventors:
• LEGER, Roger
Saint-Lambert, Quebec J4R 2V8 (CA)
• WATKINS, William, John
Sunnyvale, CA 94087 (US)
• ZHANG, Jason, Zhijia
Foster City, CA 94404 (US)
• RENAULT, Thomas, Eric
Santa Clara, CA 95051 (US)

• LEE, Ving, Jack
Los Altos, CA 94024 (US)
• OHTA, Toshiharu,
Daiichi Pharmaceutical Co., Ltd.
Edogawa-ku, Tokyo 134-8630 (JP)
• NAKAYAMA, Kiyoshi,
Daiichi Pharmaceutical Co., Ltd.
Edogawa-ku, Tokyo 134-8630 (JP)
• ISHIDA, Yohhei, Daiichi Pharmaceutical Co., Ltd.
Edogawa-ku, Tokyo 134-8630 (JP)
• OHTSUKA, Masami,
Daiichi Pharmaceutical Co., Ltd.
Edogawa-ku, Tokyo 134-8630 (JP)
• KAWATO, Haruko,
Daiichi Pharmaceutical Co., Ltd.
Edogawa-ku, Tokyo 134-8630 (JP)

(74) Representative:
Sternagel, Fleischer, Godemeyer & Partner
Patentanwälte
An den Gärten 7
51491 Overath (DE)

(54) **DRUG DISCHARGE PUMP INHIBITORS**

(57) A medicament for preventive and/or therapeutic treatment of a microbial infection having an activity of eliminating resistance of a microorganism with acquired resistance to an antimicrobial agent, which comprises as an active ingredient a compound represented by the following general formula (I), a physiologically acceptable salt thereof, or a hydrate thereof:



BEST AVAILABLE COPY

EP 1 227 084 A1

wherein R¹ and R² independently represent hydrogen atom, a halogen atom, carboxyl group and the like; J¹ represents a 5- or 6-membered heteroaromatic ring; W¹ represents -CH=CH-, -C≡C-, -CH₂CH₂- and the like; A¹ represents phenylene group, pyridinediyl group, furandiyl group and the like; G¹ represents oxygen atom, carbonyl group, ethynyl group and the like; p represents an integer of from 0 to 3; G² represents phenylene group, furandiyl group, tetrahydrofurandiyl group and the like; G³ represents -CH₂- or single bond; m and n represent an integer of 0 or 1; and Q¹ represents an acidic group.

BEST AVAILABLE COPY